Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Grenoble – page 47

663 clinical trials in Grenoble, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Grenoble at a glance
663
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

663 trials in Grenoble

Open in trial search

Bladder cancer

Not recruiting

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study on the Safety and Tolerability of Imdusiran and Durvalumab for Patients with Chronic Hepatitis B

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:AB-729
  • Sponsor:Arbutus Biopharma Inc.

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Non-small cell lung cancer stage IV+1

Not recruiting

Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Pancreatic carcinoma metastatic

Not recruiting

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer

Not recruiting

Study of Davutamig (REGN5093) for Patients with Advanced Non-Small Cell Lung Cancer with MET Alterations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Davutamig
  • Sponsor:Regeneron Pharmaceuticals Inc.

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus

Not recruiting

Study on Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Grenoble

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck cancers, multiple myeloma, and various types of leukemia. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Advanced NSCLC Treatment Studies
  • Gastric Cancer Immunotherapy
  • Hematologic Malignancies

Innovative approaches combining immunotherapy with standard treatments are showing promise in treating various forms of cancer.

02 Transplant Medicine

Clinical investigations examining kidney transplant outcomes and rejection prevention. Research focuses on new therapeutic approaches for managing transplant-related complications.

  • Antibody-Mediated Rejection
  • Novel Immunosuppression Strategies
  • Long-term Graft Survival

Studies aim to improve transplant success rates and reduce rejection incidents through innovative medication protocols.

03 Neurological Disorders

Research into narcolepsy and multiple sclerosis treatments, evaluating new therapeutic approaches for better symptom management and disease control.

  • Sleep Disorder Management
  • MS Treatment Innovations
  • Neurological Disease Progression

Cutting-edge treatments being developed to address both rare and common neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.